Prelude Therapeutics annual meeting: all director nominees elected, auditor ratified, say-on-pay approved

On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders: 1. Election of three Class III Directors, Krishna Vaddi, Paul Scherer, and Katina Dorton, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal, based on the following votes: Nominees Shares For Shares Withheld Broker Non-Votes Krishna Vaddi, Ph.D. 26,996,820 55,937 4,799,016 Paul Scherer, MD, Ph.D. 25,532,267 1,520,490 4,799,016 Katina Dorton, J.D., MBA 26,998,601 54,156 4,799,016

3. Advisory vote to approve the 2025 compensation for the Company's named executive officers, based on the following votes: Shares For Shares Against Shares Abstaining Broker Non-Votes 26,869,142 107,500 76,115 4,799,016

4. Advisory vote on the frequency of advisory votes on the compensation for the Company's named executive officers, based on the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 26,877,941 65,638 103,237 5,941 4,799,016

2. Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026, based on the following votes: Shares For Shares Against Shares Abstaining Broker Non-Votes 31,841,080 4,951 5,742 0